Cardiometabolic

Improving Population Health
Reducing Cost of Care
Enhancing the Patient Experience
Improving Provider Satisfaction

Cardiovascular Disease and Type 2 Diabetes Are Costly Comorbidities

Cardiovascular (CV) disease and type 2 diabetes (T2D) commonly co-occur and contribute to the high cost of treatment.1

The Burden of CV Disease in T2D

CV disease accounts for 28% of the cost of treating type 2 diabetes and its complications2,*

Costs Graph
Evaluate the health system population to control costs
Deeper insights into the population of patients with T2D and CV disease can help identify and manage the costs of providing treatment. Begin by evaluating the:
Chronic Care Icons Checkmark
Total number of adult patients
Chronic Care Icons Checkmark
Total CV readmissions and costs
Chronic Care Icons Checkmark
Total CV admissions and costs
Chronic Care Icons Checkmark
Potential cost savings by % reduction in CV events
Examine the prevalence and economic impact of cardio-renal-metabolic conditions at the state-, county-, and congressional district-level.
 

*Mean annualized cost per patient with event adjusted to 2016 USD; costs reflective of all-cause costs per patient. Costs reflect the proportion of total mean annual costs that are type 2 diabetes-related. Other nondiabetes-related costs are not included in the figure.2

 

Other conditions include neurologic and opthalmic. CV disease conditions include myocardial infarction, angina, heart failure, stroke, other ischemic disease, arrhythmias, cardiac arrest, atherosclerosis, peripheral vascular disease, arterial thrombosis and embolism, cardiomyopathy, endocarditis, pericarditis, myocarditis, rheumatic heart disease and fever, conduction disorders other unspecified CV disease conditions.2

 

1. Economic costs of diabetes in the U.S. in 2017. Diabetes Care. 2018;41:917-928. 2. Sander S, et al. Poster presented at American Academy of Managed Care Nexus; October 3-6, 2016; National Harbor, MD.